Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

251R-1

Sigma-Aldrich

Factor XIIIa (EP3372) Rabbit Monoclonal Primary Antibody

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Codice UNSPSC:
12352203
NACRES:
NA.41

Origine biologica

rabbit

Livello qualitativo

100
500

Coniugato

unconjugated

Forma dell’anticorpo

culture supernatant

Tipo di anticorpo

primary antibodies

Clone

EP3372, monoclonal

Descrizione

For In Vitro Diagnostic Use in Select Regions (See Chart)

Forma fisica

buffered aqueous solution

Reattività contro le specie

human

Confezionamento

vial of 0.1 mL concentrate (251R-14)
vial of 0.5 mL concentrate (251R-15)
bottle of 1.0 mL predilute (251R-17)
vial of 1.0 mL concentrate (251R-16)
bottle of 7.0 mL predilute (251R-18)

Produttore/marchio commerciale

Cell Marque

tecniche

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500

Isotipo

IgG

Controllo

dermatofibroma

Condizioni di spedizione

wet ice

Temperatura di conservazione

2-8°C

Visualizzazione

cytoplasmic

Informazioni sul gene

human ... F13A1(2162)

Categorie correlate

Descrizione generale

Factor XIIIa is a plasma transglutaminase that is part of the blood coagulation cascade and plays a critical role in stabilizing fibrin networks at the site of an injury to produce a clot. Factor XIIIa is expressed in platelets, megakaryocytes, fibroblast-like cells in the placenta, uterus, and prostate, monocytes and macrophages, and dermal dendritic cells. Anti-Factor XIIIa immunohistochemistry is used to identify fibrohistiocytic neoplasms such as dermatofibroma.
Factor XIIIa is a blood proenzyme that has been identified in platelets, megakaryocyte, and fibroblast-like mesenchymal or histiocytic cells present in the placenta, uterus, and prostate; it is also present in monocytes and macrophages and dermal dendritic cells. Anti- Factor XIIIa has been found to be useful in differentiating between dermatofibroma (90% (+)), dermatofibrosarcoma protuberans (25%(+)) and desmoplastic malignant melanoma (0%(+)). Factor XIIIa positivity is also seen in capillary hemagioblastoma (100%(+)), hemangioendothelioma (100%(+)), hemangiopericytoma (100%(+)), xanthogranuloma (100%(+)), xanthoma (100(+)), hepatocellular carcinoma (93%(+)), glomus tumor (80%(+)), and meningioma (80 % (+)).

Qualità


IVD

IVD

IVD

RUO

Linkage

Factor XIIIa Positive Control Slides , Product No. 251S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Stato fisico

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Nota sulla preparazione

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Altre note

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Note legali

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Non trovi il prodotto giusto?  

Prova il nostro Motore di ricerca dei prodotti.


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

M G Horenstein et al.
The American journal of surgical pathology, 24(7), 996-1003 (2000-07-15)
Routine histology and immunohistochemistry can usually distinguish dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP). DF generally expresses factor XIIIa whereas DFSP generally expresses CD34. The authors report 10 cutaneous fibrohistiocytic lesions combining clinical, histologic, and immunohistochemical features of both DF and
P Abenoza et al.
The American Journal of dermatopathology, 15(5), 429-434 (1993-10-01)
To assess the use of anti-CD34 and anti-factor-XIIIa antibodies for the differential diagnosis of dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP), we stained 40 DFs and 13 DFSPs. A significant population of dendritic and spindle cells was reactive with anti-factor-XIIIa in
Louis P Dehner
The American journal of surgical pathology, 27(5), 579-593 (2003-04-30)
Juvenile xanthogranulomas (JXG) is a histiocytic disorder, primarily but not exclusively seen throughout the first two decades of life and principally as a solitary cutaneous lesion. This study is a retrospective clinical and pathologic review of 174 cases documenting the
A J Demetris et al.
The American journal of surgical pathology, 21(3), 263-270 (1997-03-01)
Epithelioid hemangioendothelioma (EHE) is best considered a vascular neoplasm of intermediate malignancy. Although usually progressive, the clinical course is highly unpredictable. The present communication describes a case of extensive recurrent hepatic EHE, limited to the liver allograft and initially manifest
E J Glusac et al.
The American journal of surgical pathology, 18(6), 583-590 (1994-06-01)
Epithelioid cell histiocytoma is a recently recognized lesion that is considered to be a variant of cutaneous fibrous histiocytoma (dermatofibroma). Ten cases are presented, including their light microscopic, immunohistochemical, and ultrastructural features. Eight of the cases are similar to those

Articoli

Immunohistochemistry (IHC) techniques and applications have greatly improved, dermatopathology is still largely based on H&E stained slides.This paper outlines ways in which IHC antibodies can be utilized for dermatopathology.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.